Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers

J. Stuart Ferriss, M. Yvette Williams-Brown

Research output: Contribution to journalReview articlepeer-review

Abstract

Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.

Original languageEnglish (US)
Article number75
JournalCurrent treatment options in oncology
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2019

Keywords

  • Checkpoint inhibitors
  • Endometrial cancer
  • Gynecologic cancers
  • Immunotherapy
  • Lynch syndrome
  • Ovarian cancer
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers'. Together they form a unique fingerprint.

Cite this